RGEN Quote, Financials, Valuation and Earnings

Enovis Corp. has a net margin of 7.9% compared to Repligen Corp.'s net margin of -104%. Repligen Corp.'s return on equity of 0.09% beat Enovis Corp.'s return on equity of -52.07%.

Repligen Corp. has a consensus price target of $190.33, signalling upside risk potential of 14.1%. On the other hand Enovis Corp. has an analysts' consensus of $45.45 which suggests that it could grow by 53.15%. Given that Enovis Corp. has higher upside potential than Repligen Corp., analysts believe Enovis Corp. is more attractive than Repligen Corp..

Repligen Corp. has a beta of 1.119, which suggesting that the stock is 11.925% more volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.286, suggesting its more volatile than the S&P 500 by 28.564%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $188.8M, which are smaller than Enovis Corp. quarterly revenues of $548.9M. Repligen Corp.'s net income of $14.9M is higher than Enovis Corp.'s net income of -$570.9M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,465.89x while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.29x versus 0.75x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of 7.9% compared to Repligen Corp.'s net margin of 6.19%. Repligen Corp.'s return on equity of 0.09% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Repligen Corp. has a consensus price target of $190.33, signalling upside risk potential of 14.1%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 63.78%. Given that InfuSystem Holdings, Inc. has higher upside potential than Repligen Corp., analysts believe InfuSystem Holdings, Inc. is more attractive than Repligen Corp..

Repligen Corp. has a beta of 1.119, which suggesting that the stock is 11.925% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $188.8M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Repligen Corp.'s net income of $14.9M is higher than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,465.89x while InfuSystem Holdings, Inc.'s PE ratio is 33.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.29x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 7.9% compared to Repligen Corp.'s net margin of -862.39%. Repligen Corp.'s return on equity of 0.09% beat VolitionRX Ltd.'s return on equity of --.

Repligen Corp. has a consensus price target of $190.33, signalling upside risk potential of 14.1%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 560.66%. Given that VolitionRX Ltd. has higher upside potential than Repligen Corp., analysts believe VolitionRX Ltd. is more attractive than Repligen Corp..

Repligen Corp. has a beta of 1.119, which suggesting that the stock is 11.925% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $188.8M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Repligen Corp.'s net income of $14.9M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,465.89x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.29x versus 22.82x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 7.9% compared to Repligen Corp.'s net margin of 3.93%. Repligen Corp.'s return on equity of 0.09% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Repligen Corp. has a consensus price target of $190.33, signalling upside risk potential of 14.1%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.94%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Repligen Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than Repligen Corp..

Repligen Corp. has a beta of 1.119, which suggesting that the stock is 11.925% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Repligen Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Repligen Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Repligen Corp. quarterly revenues are $188.8M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Repligen Corp.'s net income of $14.9M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Repligen Corp.'s price-to-earnings ratio is 6,465.89x while Xtant Medical Holdings, Inc.'s PE ratio is 66.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Repligen Corp. is 13.29x versus 0.74x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.